Abstract
The multiple endocrine neoplasia (MEN) syndromes are rare autosomal dominant conditions predisposing affected individuals to benign and malignant tumors of the pituitary, thyroid, parathyroid, adrenal, endocrine, pancreas, paraganglion, or nonendocrine organs. The classic MEN syndromes include MEN type 1 (MEN1) and MEN type 2 (MEN2). The prevalence of MEN1 is estimated to be 1 in 20,000–40,000 individuals and that of MEN2 is estimated to be 1 in 35,000 individuals (DeLellis et al. 2004).
References
American Thyroid Association Guidelines Task Force, Kloos, R. T., Eng, C., Evans, D. B., et al. (2009). Medullary thyroid cancer: Management guidelines of the American Thyroid Association. Thyroid, 19, 565–612.
Brandi, M. L., Gagel, R. F., Angeli, A., et al. (2001). Guidelines for diagnosis and therapy of MEN type 1 and type 2. Journal of Clinical Endocrinology and Metabolism, 86, 5658–5671.
Brenner, M. E., & Jacene, H. A. (2008). Recurrent or residual hyperparathyroidism and thyroid cancer effectively evaluated with scintigraphy. Otolaryngologic Clinics of North America, 41, 1117–1133.
Callender, G. G., Rich, T. A., & Perrier, N. D. (2008). Multiple endocrine neoplasia syndromes [Review]. Surgical Clinics of North America, 88, 863–895.
Da Silva, A. M., Maciel, R. M., Da Silva, M. R., et al. (2003). A novel germ-line point mutation in RET exon 8 (Gly(533)Cys) in a large kindred with familial medullary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism, 88, 5438–5443.
Dean, P. G., van Heerden, J. A., Farley, D. R., et al. (2000). Are patients with multiple endocrine neoplasia type 1 prone to premature death? World Journal of Surgery, 24, 1437–1441.
DeLellis, R. A., Lloyd, R. V., Heitz, P. U., et al. (2004). Pathology and genetics: Tumours of the endocrine organs. In P. Kleihues & L. H. Sobin (Eds.), World Health Organization classification of tumours (Vol. 10, p. 257). Lyon: IARC Press.
Diaz-Thomas, A. (2014). Pediatric multiple endocrine neoplasia. Medscape Reference. Updated 22 Aug 2014. Available at: http://emedicine.medscape.com/article/923269-overview
Doherty, G. M. (2005). Multiple endocrine neoplasia type 1. Journal of Surgical Oncology, 89(2005), 143–150.
Doherty, G. M., Olson, J. A., Frisella, M. M., et al. (1998). Lethality of multiple endocrine neoplasia type I. World Journal of Surgery, 22, 581–586.
Dvorakova, S., Vaclavikova, E., Duskova, J., et al. (2005). Exon 5 of the RET proto-oncogene: A newly detected risk exon for familial medullary thyroid carcinoma, a novel germ-line mutation Gly321Arg. Journal of Endocrinological Investigation, 28, 905–909.
Eng, C., Clayton, D., Schuffenecker, I., et al. (1996). The relationship between specific ret proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2: International RET mutation consortium analysis. Journal of the American Medical Association, 276, 1575–1579.
Falchetti, A., Marini, F., Luzi, E., et al. (2008). Multiple endocrine neoplasms [Review]. Best Practice & Research. Clinical Rheumatology, 22, 149–163.
Gagel, R. F., & Marx, S. J. (2007). Multiple endocrine neoplasia. In P. R. Larsen, H. Kronenburg, S. Melmed, & K. Polonsky (Eds.), Williams textbook of endocrinology (11th ed.). Orlando: W. B. Saunders & Company, November (Section X, Chapter 40).
Gimm, O., Marsh, D. J., Andrew, S. D., et al. (1997). Germline dinucleotide mutation in codon 883 of the RET proto-oncogene in multiple endocrine neoplasia type 2B without codon 918 mutation. Journal of Clinical Endocrinology and Metabolism, 82, 3902–3904.
Giusti, f., Marini, F., & Brandi, M. L. (2015). Multiple endocrine neoplasia type 1. Updated 12 Feb 2015. Available at: http://www.ncbi.nlm.nih.gov/books/NBK1538/
Grajo, J. R., Paspulati, R. M., Sahani, D. V., et al. (2016). Multiple endocrine neoplasia syndromes. A comprehensive imaging review. Radiologic Clinics of North America, 54, 441–451.
Hoff, A. O., Cote, G. J., & Gagel, R. F. (2000). Multiple endocrine neoplasias. Annual Review of Physiology, 62, 377–411.
Krampitz, G. W., & Norton, J. A. (2014). RET gene mutations (genotype and phenotype) of multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma. Cancer, 120, 1920–1931.
Lee, M., & Pellegata, N. S. (2013a). Multiple endocrine neoplasia syndromes associated with mutation of p27. Journal of Endocrinological Investigation, 36, 781–787.
Lee, M., & Pellegata, N. S. (2013b). Multiple endocrine neoplasia type 4. Frontiers of Hormone Research, 41, 63–78.
Lewis, C. E., & Yeh, M. W. (2008). Inherited endocrinopathies: An update [Minireview]. Molecular Genetics and Metabolism, 94, 271–282.
Lips, C. J., Landsvater, R. M., Hoppener, J. W., et al. (1994). Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type2A. The New England Journal of Medicine, 331, 828–835.
Machens, A., Niccoli-Sire, P., Hoegel, J., et al. (2003). Early malignant progression of hereditary medullary thyroid cancer. The New England Journal of Medicine, 349, 1517–1525.
Marini, F., Falehetti, A., Del Monte, F., et al. (2006a). Multiple endocrine neoplasia type I. Orphanet Journal of Rare Diseases, 1, 38–46.
Marini, F., Falchetti, A., Del Monte, F., et al. (2006b). Multiple endocrine neoplasia type 2 [Review]. Orphanet Journal of Rare Diseases, 1, 45–50.
Marinoni, I., & Pellegata, N. S. (2011). p27kip1: A new multiple endocrine neoplasia gene? Neuroendocrinology, 93, 19–28.
Marquard, M. S., & Eng, C. (2015). Multiple endocrine neoplasia type 2. GeneReviews. Updated 25 June 2015. Available at: http://www.ncbi.nlm.nih.gov/books/NBK1257/
Molatore, S., & Pellegata, N. S. (2010). The MENX syndrome and p27: Relationships with multiple endocrine neoplasia. Progress in Brain Research, 182, 295–320.
Moline, J., & Eng, C. (2010). Multiple endocrine neoplasia type 2. GeneReviews. Updated 4 May 2010. Available at: http://www.ncbi.nlm.nih.gov/books/NBK1257/
Mulligan, L. M., Eng, C., Healey, C. S., et al. (1994). Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nature Genetics, 6, 70–74.
Mulligan, L. M., Marsh, D. J., Robinson, B. G., et al. (1995). Genotype-phenotype correlation in multiple endocrine neoplasia type 2: Report of the International RET Mutation Consortium. Journal of Internal Medicine, 238, 343–346.
O’Riordain, D. S., O’Brien, T., Weaver, A. L., et al. (1994). Medullary thyroid carcinoma in multiple endocrine neoplasia types 2A and 2B. Surgery, 116, 1017–1023.
Pack, S., Turner, M. L., Zhuang, Z., et al. (1998). Cutaneous tumors in patients with multiple endocrine neoplasia type 1 show allelic deletion of the MEN1 gene. The Journal of Investigative Dermatology, 110, 438–440.
Pellegata, N. S. (2012). MENX and MEN4. Clinics, 67, 13–18.
Pellegata, N. S., Quintanilla-Martinez, L., Siggelkow, H., et al. (2006). Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proceedings of National Academy of Sciences of United States of America, 103, 15558–15563.
Raue, F., & Frank-Raue, K. (2012). Genotype-phenotype correlation in multiple endocrine neoplasia type 2. Clinics, 67(S1), 69–75.
Richards, M. L. (2015). Multiple endocrine neoplasia, type 2. Medscape Reference. Updated 11 Dec 2015. Available at: http://emedicine.medscape.com/article/123447-overview
Romei, C., Pardi, E., Cetani, F., et al. (2012). Genetic and clinical features of multiple endocrine neoplasia types 1 and 2. Journal of Oncology, 2012, 1915.
Santoro, M., Carlomagno, F., Melillo, R. M., et al. (2004). Dysfunction of the RET receptor in human cancer. Cellular and Molecular Life Sciences, 61, 2954–2964.
Schimke, R. N., Hartmann, W. H., Prout, T. E., et al. (1968). Syndrome of bilateral pheochromocytoma, medullary thyroid carcinoma and multiple neuromas. A possible regulatory defect in the differentiation of chromaffin tissue. The New England Journal of Medicine, 279, 1–7.
Schuffenecker, I., Billaud, M., Calender, A., et al. (1994). RET proto-oncogene mutations in French MEN 2A and FMTC families. Human Molecular Genetics, 3, 1939–1943.
Schussheim, D. H., Skarulis, M. C., Agarwal, S. K., et al. (2001). Multiple endocrine neoplasia type 1: New clinical and basic findings. Trends in Endocrinology and Metabolism, 12, 173–178.
Thakker, R. V. (2001). Multiple endocrine neoplasia. Hormone Research, 56, 67–72.
Thakker, R. V., Newey, P. J., Walls, G. V., et al. (2012). Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). Journal of Clinical Endocrinology and Metabolism, 97, 2990–3011.
Vortmeyer, A. O., Böni, R., Pack, S. D., et al. (1999). Perivascular cells harboring multiple endocrine neoplasia type 1 alterations are neoplastic cells in angiofibromas. Cancer Research, 59, 274–278.
Wilkinson, S., Teh, B. T., Davey, K. R., et al. (1993). Cause of death in multiple endocrine neoplasia type 1. Archives of Surgery, 128, 683–690.
Wray, C. J., Rich, T. A., Waguespack, S. G., et al. (2008). Failure to recognize multiple endocrine neoplasia 2B: More common than we think? Annals of Surgical Oncology, 15, 293–301.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media LLC
About this entry
Cite this entry
Chen, H. (2017). Multiple Endocrine Neoplasia Syndromes. In: Atlas of Genetic Diagnosis and Counseling. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-2401-1_168
Download citation
DOI: https://doi.org/10.1007/978-1-4939-2401-1_168
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4939-2400-4
Online ISBN: 978-1-4939-2401-1
eBook Packages: MedicineReference Module Medicine